Latest Pharma and Biotech News
Biotechnology
30 December 2024 Antibody-drug conjugates (ADCs) combine monoclonal antibody (MAb) specificity with cytotoxic drug potency via a linker, delivering targeted cancer therapy. ADCs concentrate treatment at tumor sites, enhancing efficacy while minimizing harm to healthy tissues.
Today's issue
Refine Search
Pharmaceutical
Shares in Californian company Biomea Fusion were down almost 60% ahead of the opening bell on Friday, after news of a regulatory setback. 7 June 2024
Pharmaceutical
US healthcare giant Johnson & Johnson continued its M&A spending spree during May. 6 June 2024
Pharmaceutical
Privately-held UK firm Cycle Pharmaceuticals, which is focused on rare diseases, is seeking to acquire US biopharma Vanda Pharmaceuticals. 6 June 2024
Pharmaceutical
Singaporean speciality pharma company Hyphens Pharma International has entered into an exclusive license, development and commercialization agreement with Japanese drugmaker Maruho. 6 June 2024
Pharmaceutical
Australian radiopharma developer Telix Pharmaceuticals has announced the launch of its initial public offering in the USA of 17,000,000 American Depositary Shares (ADSs), each representing one ordinary share in Telix. 6 June 2024
Pharmaceutical
The race to secure market share for GLP-1 agonists continues to develop, with Eli Lilly revealing more promising results for its option, tirzepatide. 6 June 2024
Pharmaceutical
Ireland-headquartered Mallinckrodt has released new data on Terlivaz (terlipressin) for injection in patients with hepatorenal syndrome (HRS) with rapid reduction in kidney function. 6 June 2024
Pharmaceutical
US biotech major Gilead Sciences has announced two-year interim results from the ongoing ASSURE study of investigational seladelpar for the treatment of primary biliary cholangitis (PBC), a rare, chronic inflammatory liver disease. 5 June 2024
Pharmaceutical
Italy’s Philogen and Indian drugmaker Sun Pharmaceutical Industries have submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the approval of Nidlegy (daromun). 5 June 2024
Pharmaceutical
Russian drugmaker Nanolek plans to accelerate its expansion this year by expanding its range and increase of output, paying a particular focus to vaccines, The Pharma Letter’s local correspondent reports. 5 June 2024
Pharmaceutical
Lykos Therapeutics’ hopes of being the first to market with a hallucinogenic medicine suffered a major blow Tuesday during a meeting of the US Food and Drug Administration's (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC). 5 June 2024
Pharmaceutical
Ireland-headquartered fish oil-based heart drug specialist Amarin Corporation announced that it has appointed Aaron Berg, currently Amarin’s executive vice president and president of the US business, as president and chief executive (CEO). 5 June 2024
Pharmaceutical
San Diego, USA-based biopharma company Viking Therapeutics has announced favorable 52-week results from its Phase IIb VOYAGE study of VK2809. 5 June 2024
Pharmaceutical
Japanese pharma major Takeda has presented positive results from its Phase IIb trial of TAK-861 at the SLEEP 2024 annual meeting. 4 June 2024
Pharmaceutical
Japanese pharma major Shionogi says it is responding to the urgent global need for additional antimicrobial research and development by establishing its first discovery laboratory in San Diego, California, USA. 4 June 2024
Pharmaceutical
UK drugmaker GSK closed 9% lower after Monday’s trading in London on news of a negative court ruling. 4 June 2024
Pharmaceutical
The attention-deficit/hyperactivity disorder (ADHD) market across the seven major markets (7MM) is forecast to decline at a negative compound annual growth rate (CAGR) of 0.9% from $11.9 billion in 2022 to $10.9 billion in 2032. 4 June 2024
Pharmaceutical
Bladder cancer specialist UroGen Pharma has appointed David Lin as chief commercial officer. 4 June 2024
Pharmaceutical
Privately-held company GAIA has had more than a front-row seat to observe the arrival of digital therapeutics and applications of AI in pharma over the past quarter century. 4 June 2024
Pharmaceutical
USA-based tumor drug resistance specialist Deciphera Pharmaceuticals today announced results from the company’s MOTION pivotal Phase III study of vimseltinib in patients with Tenosynovial Giant Cell Tumor TGCT) in an oral presentation at ASCO. 3 June 2024
All news
Pharmaceutical
Full mergers and acquisitions in the pharmaceutical and biotechnology in 2024 fluctuated throughout the year with hardly any in some months and a significant number in other. But one thing was clear – buyers were shying away from big bets on commercially ready medicines in favor of earlier stage drug developers. 3 January 2025
Pharmaceutical
Regeneron Pharmaceuticals has acquired UK-based biotech Oxular, enhancing its gene therapy development program with the firm’s specialized ocular delivery tech. 3 January 2025
Pharmaceutical
One of the most promising areas of medical innovation in the next five years is immuno-oncology (I-O)/cancer therapeutics represent, fundamentally transforming how cancer is treated. 3 January 2025
Pharmaceutical
Massachusetts, USA-based based brain disease biotech Neumora Therapeutics shares tumbled 81.4% to 1.97 after it revealed that its experimental depression treatment failed in the first of three studies planned by the biotech company. 3 January 2025
Pharmaceutical
Hutchmed has announced agreements to divest its 45% equity stake in Shanghai Hutchison Pharmaceuticals Limited (SHPL) for $608 million in cash. The buyers are GP Health Service Capital and Shanghai Pharmaceuticals. 2 January 2025
Pharmaceutical
Kazia Therapeutics, an oncology-focused Australian drug developer, has been advised by the US Food and Drug Administration (FDA) that accelerated approval for its brain cancer drug, paxalisib, is unlikely. 2 January 2025
Pharmaceutical
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) under the accelerated approval pathway for avutometinib, an oral RAF/MEK clamp, in combination with defactinib. 2 January 2025
Pharmaceutical
The new $2,000 cap on out-of-pocket costs for prescription drugs went into effect as of January 1, 2025, the US Department of Health and Human Services (HHS) Secretary Xavier Becerra has announced. 2 January 2025
Pharmaceutical
The market for artificial intelligence (AI) in cancer care is projected to grow from $2.2 billion in 2024 to $6.3 billion by 2029, reflecting a growth rate of 23.1%, according to a recent study by BCC Research. 31 December 2024
Pharmaceutical
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Winrevair (sotatercept) to treat pulmonary arterial hypertension (PAH), from US pharma giant Merck & Co. 31 December 2024
Pharmaceutical
US CNS specialist Axsome Therapeutics yesterday announced the completion of its Phase III clinical program evaluating AXS-05 (dextromethorphan-bupropion). 31 December 2024
Pharmaceutical
It has been a year since the launch of Zepbound (tirzepatide) for obesity, and US pharma major Eli Lilly’s competition with Denmark’s Novo Nordisk continues. 31 December 2024
Pharmaceutical
The US Food and Drug Administration (FDA) is reopening the comment period for the Federal Register notice (FRN), “Evaluating the Immunogenicity Risk of Host Cell Proteins in Follow-on Recombinant Peptide Products: Establishment of a Public Docket: Request for Information and Comments” due to high interest from industry. 31 December 2024
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has issued a warning urging the public to avoid purchasing weight-loss medicines without a prescription. 30 December 2024
Pharmaceutical
For many in the life sciences, the year gone by has been marked by volatility across a range of metrics, as political and economic disruptions threaten to upend the standard operating model. 30 December 2024
Pharmaceutical
China’s National Medical Products Administration (NMPA) has recently approved Zorifer (zorifertinib), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) specifically for the treatment of non-small cell lung cancer (NSCLC) with CNS metastases. 30 December 2024
Pharmaceutical
The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved the use of Hyqvia (immune globulin infusion 10% [human] with recombinant human hyaluronidase) in patients with agammaglobulinemia or hypogammaglobulinemia disorders, from domestic drug giant Takeda Pharma 27 December 2024
Pharmaceutical
Japanese drugmaker Kaken Pharmaceutical has entered into a license agreement with US healthcare giant Johnson & Johnson for the global development, manufacturing and commercialization of a STAT6 program that Kaken is developing. 27 December 2024
Pharmaceutical
Akums, India’s largest contract development and manufacturing organization (CDMO), has signed a strategic agreement with an undisclosed global pharmaceutical company. 27 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze